Your email has been successfully added to our mailing list.

×
0 0 0.0390804597701149 0.0390804597701149 0.0390804597701149 0.0390804597701149 0.0413793103448275 0.0459770114942527
Stock impact report

AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

AVROBIO, Inc. (AVRO)  More Company Research Source: Business Wire
Last avrobio, inc. earnings: 11/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.avrobio.com/investor-relations
PDF Safety data updates for Phase 1 and 2 Fabry disease clinical trials and Phase 1/2 Gaucher disease type 1 clinical trial show no adverse events or serious adverse events related to drug product CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a vision to free people from a lifetime of genetic disease, today hosted a panel of investigators managing the patient experience in the Phase 2 FAB-GT clinical trial of AVR-RD-01, an investigational one-time gene therapy for Fabry disease, at the 14th International Congress of Inborn Errors of Metabolism (ICIEM), Nov. 21-23, 2021, in Sydney, Australia. Other presentations included updated safety data from the first lentiviral gene therapy clinical trials for Fabry disease and Gaucher disease type 1, as well as 10- to 12-month safety data from gene therapy-treated mice with mucopolysaccharidosis type II (MPSII), or Hunter syndrome.Chaired by Rob Wynn, M.D., (consultant pediatric [Read more]
Impact snapshot Event time: AVRO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
AVRO alerts

from News Quantified
Opt-in for
AVRO alerts

from News Quantified